» Articles » PMID: 37361328

Galectin-3 and RAGE Differentially Control Advanced Glycation Endproduct-induced Collagen Damage in Murine Intervertebral Disc Organ Culture

Overview
Journal JOR Spine
Specialty Orthopedics
Date 2023 Jun 26
PMID 37361328
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Back and neck pain are leading causes of global disability that are associated with intervertebral disc (IVD) degeneration. Causes of IVD degeneration are multifactorial, and diet, age, and diabetes have all been linked to IVD degeneration. Advanced glycation endproducts (AGEs) accumulate in the IVD as a result of aging, diet, and diabetes, and AGE accumulation in the IVD has been shown to induce oxidative stress and catabolic activity that result in collagen damage. An association between AGE accumulation and IVD degeneration is emerging, yet mechanism behind this association remains unclear. The Receptor for AGEs (RAGE) is thought to induce catabolic responses in the IVD, and the AGE receptor Galectin 3 (Gal3) had a protective effect in other tissue systems but has not been evaluated in the IVD.

Methods: This study used an IVD organ culture model with genetically modified mice to analyze the roles of RAGE and Gal3 in an AGE challenge.

Results: Gal3 was protective against an AGE challenge in the murine IVD ex vivo, limiting collagen damage and biomechanical property changes. Gal3 receptor levels in the AF significantly decreased upon an AGE challenge. RAGE was necessary for AGE-induced collagen damage in the IVD, and RAGE receptor levels in the AF significantly increased upon AGE challenge.

Discussion: These findings suggest both RAGE and Gal3 are important in the IVD response to AGEs and highlight Gal3 as an important receptor with protective effects on collagen damage. This research improves understanding the mechanisms of AGE-induced IVD degeneration and suggests Gal3 receptor modulation as a potential target for preventative and therapeutic treatment for IVD degeneration.

Citing Articles

Immortalized Schwann cell lines as useful tools for pathogenesis-based therapeutic approaches to diabetic peripheral neuropathy.

Sango K, Yako H, Niimi N, Takaku S Front Endocrinol (Lausanne). 2025; 15:1531209.

PMID: 39906036 PMC: 11790431. DOI: 10.3389/fendo.2024.1531209.


Collagen integrity of the annulus fibrosus in degenerative disc disease individuals quantified with collagen hybridizing peptide.

Dhiman M, Bader T, Ponjevic D, Salo P, Hart D, Swamy G JOR Spine. 2024; 7(3):e1359.

PMID: 39092166 PMC: 11291301. DOI: 10.1002/jsp2.1359.


Role of Galectin-3 in intervertebral disc degeneration: an experimental study.

Li J, Han N, Liu Z, Osman A, Xu L, Song J BMC Musculoskelet Disord. 2024; 25(1):249.

PMID: 38561725 PMC: 10983641. DOI: 10.1186/s12891-024-07382-5.


From hyperglycemia to intervertebral disc damage: exploring diabetic-induced disc degeneration.

Li S, Du J, Huang Y, Gao S, Zhao Z, Chang Z Front Immunol. 2024; 15:1355503.

PMID: 38444852 PMC: 10912372. DOI: 10.3389/fimmu.2024.1355503.


Galectin-3 and RAGE differentially control advanced glycation endproduct-induced collagen damage in murine intervertebral disc organ culture.

Gallate Z, DErminio D, Nasser P, Laudier D, Iatridis J JOR Spine. 2023; 6(2):e1254.

PMID: 37361328 PMC: 10285763. DOI: 10.1002/jsp2.1254.

References
1.
Alpantaki K, Kampouroglou A, Koutserimpas C, Effraimidis G, Hadjipavlou A . Diabetes mellitus as a risk factor for intervertebral disc degeneration: a critical review. Eur Spine J. 2019; 28(9):2129-2144. DOI: 10.1007/s00586-019-06029-7. View

2.
Adams M, Roughley P . What is intervertebral disc degeneration, and what causes it?. Spine (Phila Pa 1976). 2006; 31(18):2151-61. DOI: 10.1097/01.brs.0000231761.73859.2c. View

3.
Kanai M, Goke M, Tsunekawa S, Podolsky D . Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem. 1997; 272(10):6621-8. DOI: 10.1074/jbc.272.10.6621. View

4.
Vlassara H, Striker G . AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011; 7(9):526-39. PMC: 3708644. DOI: 10.1038/nrendo.2011.74. View

5.
Noriega D, Zenker H, Croes C, Ewaz A, Ruinemans-Koerts J, Savelkoul H . Receptor Mediated Effects of Advanced Glycation End Products (AGEs) on Innate and Adaptative Immunity: Relevance for Food Allergy. Nutrients. 2022; 14(2). PMC: 8778532. DOI: 10.3390/nu14020371. View